|
186 Products |
| 186 Products |
|
1696 Diseases |  |
94663 News |  |
| «12...345678910111213...10631064» |
- fludrocortisone / Generic mfg., hydrocortisone / Generic mfg.
EFFICACY AND SAFETY OF FLUDROCORTISONE PLUS HYDROCORTISONE VS HYDROCORTISONE ALONE OR PLACEBO IN PATIENTS WITH SEPTIC SHOCK: A SYSTEMATIC REVIEW AND META-ANALYSIS (Convention Center Exhibit Hall: Rapid Fire Area 2A) - Sep 11, 2024 - Abstract #CHEST2024CHEST_5987;
CLINICAL IMPLICATIONS: This meta-analysis suggests that using both fludrocortisone and hydrocortisone may provide a survival benefit among patients with septic shock, particularly by lowering in-hospital mortality. Further research is needed to elucidate the long-term outcomes.
- Vistide (cidofovir) / Gilead
SUCCESSFUL TREATMENT OF ADENOVIRUS INDUCED ARDS WITH CIDOFOVIR (Convention Center Exhibit Hall: Poster Area 2) - Sep 11, 2024 - Abstract #CHEST2024CHEST_5928;
The use of cidofovir has been proven in immunocompromised patients, but there is limited evidence of its use in immunocompetent populations. Our case demonstrates another use in the immunocompetent patient and can yield more information about treatment of adenovirus in patients that are critically ill.
- Airsupra (budesonide/salbutamol) / AstraZeneca, Avillion
EFFICACY OF ALBUTEROL-BUDESONIDE RESCUE ON TOP OF INHALED CORTICOSTEROID/LONG-ACTING ?-AGONIST (LABA) ASTHMA MAINTENANCE THERAPY CONTAINING FORMOTEROL OR OTHER LABA (MANDALA) (Convention Center Exhibit Hall: Rapid Fire Area 3C) - Sep 11, 2024 - Abstract #CHEST2024CHEST_5924;
P3
In this post-hoc analysis, as-needed albuterol-budesonide 180/160 ?g reduced severe asthma exacerbation risk versus albuterol in patients on ICS-LABA maintenance; the magnitude of benefit was similar regardless of whether the LABA component was formoterol or another LABA. CLINICAL IMPLICATIONS: Many patients with moderate-to-severe asthma receive ICS
- | cyclophosphamide / Generic mfg., dexamethasone injection / Generic mfg.
Journal, IO biomarker: Pearls & Oy-sters: Tumour-Like Mass Lesion Secondary to Primary CNS Vasculitis. (Pubmed Central) - Sep 10, 2024
Noncontrast head CT was suggestive of glioma, resulting in intravenous dexamethasone administration and admission to neurosurgery...Treatment with corticosteroids and cyclophosphamide resulted in sustained clinical and radiologic improvement...The most important mimicker is CNS lymphoma, which has a similar imaging and histologic pattern. If individuals with tumefactive PCNSV do not have a sustained immunotherapy response, repeat biopsy should be promptly performed.
- || Rituxan (rituximab) / Roche
Review, Journal: An unusual case of early onset opsoclonus-myoclonus syndrome: Case report and literature review. (Pubmed Central) - Sep 10, 2024
Despite the range of therapeutic options for managing opsoclonus-myoclonus syndrome described in the literature, the efficacy of these available therapies needs to be better established. A modified upfront approach with dexamethasone and intravenous immunoglobulin could be an option in settings where rituximab is unavailable.
- || Review, Journal: COVID-19 positive woman presented with major fetal congenital anomalies: A case report with literature review. (Pubmed Central) - Sep 10, 2024
The impact of COVID-19 exposure on neonatal outcomes has not yet been fully evaluated; in this article, we aim to find if COVID-19 exposure is linked to congenital anomalies. Further research is needed to ascertain neonatal outcomes.
- | epinephrine / Generic mfg.
Journal: When anaphylactic shock meets epinephrine and blood lactate increases: A case report. (Pubmed Central) - Sep 10, 2024
This case illustrates the importance of recognizing epinephrine-induced lactate elevation in anaphylactic shock, necessitating a nuanced interpretation of lactate dynamics. Clinicians must differentiate between lactate elevations due to tissue hypoperfusion and those arising from epinephrine's pharmacologic effects to optimize patient care.
- | Kymriah (tisagenlecleucel-T) / Novartis
Journal, Intubation: Transformed follicular lymphoma with laryngeal edema requiring tracheal intubation after tisagenlecleucel treatment: A case report. (Pubmed Central) - Sep 10, 2024
Third, TCZ, as well as DEX, may be inadequate. In such cases, we should recognize L-CRS and manage it early because it may eventually progress to laryngeal edema that requires securing the airway.
- Blenrep (belantamab mafodotin-blmf) / GSK
Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin, pomalidomide, dexamethasone vs pomalidomide plus bortezomib, dexamethasone (PVd) in relapsed/refractory multiple myeloma (101 A1-A2, Convention Center) - Sep 10, 2024 - Abstract #IMW2024IMW_244;
P3
DREAMM-8 demonstrated a statistically significant and clinically meaningful PFS benefit with BPd vs PVd in RRMM with ?1 prior LOT. BPd led to deeper and more durable responses, showed a favorable OS trend, and had a manageable safety profile.
- Ninlaro (ixazomib) / Takeda, iberdomide (CC-220) / BMS
All oral triplet Iberdomide Ixazomib and Dexamethasone in elderly patients with multiple myeloma patients at first relapse: results of the IFM phase 2 study I2D (101 A1-A2, Convention Center) - Sep 10, 2024 - Abstract #IMW2024IMW_243;
P2
Introduction: The triplet combination daratumumab, lenalidomide and dexamethasone (DRd) and bortezomib, lenalidomide and dexamethasone (VRd) are to date the standard of care for patients with transplant ineligible (TI) newly diagnosed multiple myeloma (MM)...Iberdomide is a novel oral cereblon E3 ligase modulator (CELMoD) that demonstrated promising activity in MM patients refractory to lenalidomide/pomalidomide... Overall, the oral triplet iberdomide, ixazomib and dexamethasone demonstrated a favorable efficacy / safety profile in elderly MM patients at first relapse, including patients with lenalidomide and daratumumab refractory disease.
- sonrotoclax (BGB-11417) / BeiGene
Sonrotoclax plus dexamethasone was tolerable and demonstrated antimyeloma activity in patients with relapsed/refractory multiple myeloma harboring t(11; 14) (101 A1-A2, Convention Center) - Sep 10, 2024 - Abstract #IMW2024IMW_242;
P1/2
With longer follow-up, sonrotoclax plus dexamethasone demonstrated a manageable safety profile, with low hematologic toxicity and infection rates. The combination provided deep and durable responses in this R/R population.
- belantamab (GSK2857914) / GSK
Results of a phase 1 clinical trial of belantamab mafadotin (BelMaf) combined with carfilzomib, lenalidomide, and dexamethasone (KRd) for multiple myeloma (MM) after one prior line of therapy (LOT) (101 A1-A2, Convention Center) - Sep 10, 2024 - Abstract #IMW2024IMW_241;
KRd-BelMaf demonstrated deep responses in pts with high-risk features, including HRCGs and R refractory disease. Keratopathy was frequent but manageable with dose delays and reductions.
- Tazverik (tazemetostat) / Ipsen, mezigdomide (CC-92480) / BMS
Mezigdomide (MEZI), tazemetostat (TAZ), and dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): preliminary results from the CA057-003 trial (101 A1-A2, Convention Center) - Sep 10, 2024 - Abstract #IMW2024IMW_240;
P1/2
The third agent in each combination intervenes on a key oncogenic pathway upregulated in RRMM: 1) EZH2 inhibitor TAZ for PRC2 complex dysregulation; 2) BET inhibitor BMS-986158 for CKS1B (on chromosome 1q) amplification; 3) or MEK inhibitor trametinib for RAS-RAF-MEK-ERK activation. MEZI+TAZ+DEX showed promising preliminary efficacy and safety in pts with RRMM, with no new safety concerns.
- dexamethasone / Generic mfg.
p300 catalytic inhibition selectively disrupts IRF4 oncogenic programs impacting multiple myeloma cell growth and survival (101 B1-B2, Convention Center) - Sep 10, 2024 - Abstract #IMW2024IMW_236;
Since most successful regimens in MM therapy are combinatorial, we evaluated the activity of KB528 in combination with existing SOC agents and observed synergistic activity in combination with IMiDs and dexamethasone. IRF4 dependency is a hallmark of MM that has been challenging to target with existing therapies and this study lays the groundwork for developing p300 KAT inhibitors for MM therapy.
- Ninlaro (ixazomib) / Takeda
Proteasome inhibitor-augmented salvage autologous stem cell transplantation for first relapse management in Relapsed Multiple Myeloma. (101 A1-A2, Convention Center) - Sep 10, 2024 - Abstract #IMW2024IMW_234;
MRD-ve rates, in those evaluable, rise from 8.7% post-ITD to 25.3% at D100. Augmented HDM showed a trend towards improved DoR and reduced PD, but this must be balanced against the increased toxicity of this approach, meaning PIs in the sASCT setting may be best reserved for re-induction and post-sASCT consolidation/maintenance therapy (Cook et al, Blood 2023).
- Sarclisa (isatuximab-irfc) / Sanofi
Interim Results of a Phase 2 Trial of Isatuximab-Lenalidomide for Patients with High-Risk Smoldering Multiple Myeloma (101 A1-A2, Convention Center) - Sep 10, 2024 - Abstract #IMW2024IMW_232;
P3
Compared with the natural history of PETHEMA HRSMM patients (Perez-Persona et al. Blood 2007), treatment with ISA-LEN delayed progression to symptomatic myeloma.
- Blenrep (belantamab mafodotin-blmf) / GSK
Belantamab mafodotin, pomalidomide, and dexamethasone vs pomalidomide, bortezomib, and dexamethasone in patients with relapsed/refractory multiple myeloma: patient-reported outcomes from DREAMM-8 (101 A1-A2, Convention Center) - Sep 10, 2024 - Abstract #IMW2024IMW_230;
P3
The phase 3, open-label, randomized DREAMM-8 trial (NCT04484623) met its primary endpoint of a statistically significant progression-free survival (PFS) benefit favoring belamaf, pomalidomide, and dexamethasone (BPd) vs pomalidomide, bortezomib, and dexamethasone (PVd) in patients with relapsed/refractory multiple myeloma (RRMM) who had received ?1 prior therapy, including lenalidomide. Treatment with BPd or PVd in patients with RRMM resulted in stable health-related QOL over time and was generally well tolerated by patients.
- Carvykti (ciltacabtagene autoleucel) / J&J
Overall Survival (OS) With Ciltacabtagene Autoleucel (Cilta-cel) Versus Standard of Care (SoC) in Lenalidomide (Len)-Refractory Multiple Myeloma (MM): Phase 3 CARTITUDE-4 Study Update (101 A1-A2, Convention Center) - Sep 10, 2024 - Abstract #IMW2024IMW_220;
At ~3 years of follow-up, cilta-cel significantly extended OS, reducing the risk of death vs SoC by 45%, and significantly improved quality-of-life measures vs SoC. Collectively, these data continue to support the overall benefit-risk profile of cilta-cel vs SoC in pts with len-refractory MM as early as after first relapse.
- Sarclisa (isatuximab-irfc) / Sanofi
Efficacy and safety of Isa-KRd induction before response-adapted consolidation in transplant eligible newly diagnosed multiple myeloma: an interim analysis of the IFM2020-02 MIDAS study. (Plenary Hall, Pavilion 3) - Sep 10, 2024 - Abstract #IMW2024IMW_219;
P3
No new safety signals were observed. The ongoing MIDAS study needs further follow-up for final analysis.
- Darzalex Faspro (daratumumab and hyaluronidase-fihj) / J&J
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study (Plenary Hall, Pavilion 3) - Sep 10, 2024 - Abstract #IMW2024IMW_210;
In pts with TIE or transplant-deferred NDMM, DARA SC + VRd significantly improved PFS vs VRd, reducing the risk of progression or death by 43%. D-VRd significantly increased overall MRD negativity,
- Sarclisa (isatuximab-irfc) / Sanofi
Association of Cardiac biomarkers and Adverse Events with a Carfilzomib-containing Quadruplet in High-risk Newly Diagnosed Multiple Myeloma Patients: Correlative Program of the GMMG-CONCEPT Trial (101 B1-B2, Convention Center) - Sep 10, 2024 - Abstract #IMW2024IMW_199;
P2
Elevated levels of NT-proBNP are common in newly diagnosed HR MM pts, but neither the baseline value nor an early change from baseline within the first 3 IND cycles are predictive for CVAEs. In contrast, hsTropI is rarely elevated, but baseline levels below < 2.9 ng/L were negative predictive for the occurrence of CVAE during Isa-KRd quadruplet treatment for high-risk MM.
- Darzalex (daratumumab) / J&J
Liquid chromatography mass spectrometry (LC-MS) for identification of exceptional responders in newly diagnosed multiple myeloma (NDMM). (101 B1-B2, Convention Center) - Sep 10, 2024 - Abstract #IMW2024IMW_198;
P2
LC-MS(-) and/or 10-6 MRD(-) patients experience long term disease control. The potential of LC-MS to enhance the prognostic potential of MRD at 10-6 for predicting longer disease control is currently under evaluation in a larger sample set.
- Darzalex (daratumumab) / J&J, iberdomide (CC-220) / BMS
Iberdomide, daratumumab, and dexamethasone (IberDd) in transplant-ineligible (TNE) newly diagnosed multiple myeloma (NDMM): results from the CC-220-MM-001 trial (101 A1-A2, Convention Center) - Sep 10, 2024 - Abstract #IMW2024IMW_194;
P1/2
Similar results were observed across dose levels. IberDd is being evaluated in an ongoing phase 3 trial in RRMM, and these data further support the evaluation of IBER in NDMM.
- Sarclisa (isatuximab-irfc) / Sanofi
Isatuximab plus lenalidomide and dexamethasone with bortezomib versus isatuximab plus lenalidomide and dexamethasone in newly diagnosed transplant ineligible Multiple Myeloma: The BENEFIT study. (101 A1-A2, Convention Center) - Sep 10, 2024 - Abstract #IMW2024IMW_193;
Isa-VRd significantly increased MRD end points, including the 18-month negative rate at 10-5 , the primary end point, compared to IsaRd. This study proposes Isa-VRd as a new standard of care for NDMM TI non-frail patients.
- Sarclisa (isatuximab-irfc) / Sanofi
Phase 3 study results of isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) versus VRd for transplant-ineligible patients with newly diagnosed multiple myeloma (IMROZ) (101 A1-A2, Convention Center) - Sep 10, 2024 - Abstract #IMW2024IMW_191;
P3
Safety was consistent with addition of Isa to VRd. These results support Isa-VRd as a potential new SOC in pts not intended for transplant.
- Ninlaro (ixazomib) / Takeda, Cotellic (cobimetinib) / Exelixis, Roche
Single cell analyses of bone marrow immune microenvironment in RRMM subjects treated with MEK1/2 inhibitors reveal IRF1-mediated IFN/PDL1 signaling axes (101 B1-B2, Convention Center) - Sep 10, 2024 - Abstract #IMW2024IMW_188;
P1/2
These data indicate that targeted kinase inhibition with cobi-dex activates IRF1-mediated IRF1/IFNg and PD-L1 signaling axes in the tumor microenvironment of RRMM subjects. These results support further explorations of rational combinations of targeted and immune therapies for greater efficacy in this disease.
- Sarclisa (isatuximab-irfc) / Sanofi
Isa-KRd in High-Risk Newly Diagnosed Multiple Myeloma (101 A1-A2, Convention Center) - Sep 10, 2024 - Abstract #IMW2024IMW_183;
P2
These data from our CONCEPT trial underline the high potency of Isa-KRd to not only induce but also maintain MRD neg remissions in HR NDMM pts irrespective of transplant status. Six years after treatment initiation, more than half of these HR pts are still alive and progression-free.
- Darzalex (daratumumab) / J&J
Daratumumab (DARA)/Bortezomib/Lenalidomide/Dexamethasone (D-VRd) With D-R Maintenance (Maint) in Transplant-eligible (TE) Newly Diagnosed Myeloma (NDMM): PERSEUS Cytogenetic Risk Analysis (101 A1-A2, Convention Center) - Sep 10, 2024 - Abstract #IMW2024IMW_181;
DARA plus VRd ind/consol and R maint improved PFS and induced higher rates of deep and sustained responses vs VRd ind/consol and R maint across all cytogenetic risk subgroups. These data support D-VRd ind/consol and D-R maint as a new standard of care for TE NDMM, regardless of cytogenetic risk status.
- Darzalex (daratumumab) / J&J
Daratumumab (DARA) + Bortezomib/Thalidomide/Dexamethasone (D-VTd) and DARA Maintenance in Transplant-eligible Newly Diagnosed Multiple Myeloma (NDMM): CASSIOPEIA Minimal Residual Disease (MRD) Update (101 A1-A2, Convention Center) - Sep 10, 2024 - Abstract #IMW2024IMW_180;
P3
Furthermore, receiving DARA maint offers PFS benefit regardless of MRD status. These data support the use of D-VTd ind/conso as a standard of care in TE NDMM pts and demonstrate the additional benefit of DARA monotherapy use during maint for up to 2 y.
- Blenrep (belantamab mafodotin-blmf) / GSK
Belantamab Mafodotin in Combination with VRd for the Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: Results from the Phase II, Open Label, Multicenter, GEM-BELA-VRd Trial (101 A1-A2, Convention Center) - Sep 10, 2024 - Abstract #IMW2024IMW_179;
Belamaf-VRD resulted in manageable eye-related AEs, expected hematological toxicity and respiratory infections, also due to the impact of the COVID -19 pandemic during trial recruitment. Besides, this combination was effective with a deepening of the response over time in TE NDMM.
- dexamethasone / Generic mfg.
Validation of the Steroid Symptom Questionnaire Multiple Myeloma (SSQ-MM) with concurrent symptom and quality of life measurement (EORTC QLQ-C30 and MY20) (204A, Convention Center) - Sep 10, 2024 - Abstract #IMW2024IMW_176;
This study provides evidence in support of the validity and reliability of the SSQ-MM. It is suitable for clinical use to detect steroid toxicity and improve treatment outcomes for MM patients and for use in research settings to assess the impact of steroids in MM.
- Protocol for Outpatient Administration of Multiple Myeloma Bispecific Antibodies Step-Up Dosing (204A, Convention Center) - Sep 10, 2024 - Abstract #IMW2024IMW_175;
It is suitable for clinical use to detect steroid toxicity and improve treatment outcomes for MM patients and for use in research settings to assess the impact of steroids in MM. Introduction: Teclistamab (Tecvayli
- Talvey (talquetamab-tgvs) / J&J
The real world experience of the incidence, assessment, and management of oral adverse events and weight loss with talquetamab leading to the development of an assessment tool (204A, Convention Center) - Sep 10, 2024 - Abstract #IMW2024IMW_163;
Grading the severity of oral AEs was a limitation in this study due to inconsistencies in documentation across practitioners and a lack of a standardize assessment tool for dysgeusia. Based on symptoms observed in our practice we have developed the Sinai dysgeusia evaluation tool (SiDET) that can identify the impact of dysgeusia and can be applied to evaluate the effectiveness of interventions for dysgeusia and determine if dose adjustments are warranted.
- | dexamethasone / Generic mfg.
Journal, Metabolomic study: Metabolomics to investigate the effect of preconditioned mesenchymal stem cells with crocin on pulmonary epithelial cells exposed to 2-chloroethyl ethyl sulfide. (Pubmed Central) - Sep 9, 2024
This study meticulously assesses the metabolite profiles of cells treated with Crocin, Dexamethasone, and mesenchymal stem cells (MSCs) under oxidative stress induced by 2-chloroethyl ethyl sulfide (CEES)...These findings demonstrate the potent capacity of the analyzed treatments to effectively reduce inflammation, mitigate reactive oxygen species production, and enhance cell survival rates. SIGNIFICANCE.
- | budesonide / Generic mfg.
Journal: Effects of the anti-inflammatory drug budesonide on the gut microbiota and cytokine production of 13-lined ground squirrels during pre-hibernation fattening. (Pubmed Central) - Sep 9, 2024
Overall, budesonide treatment affected the microbial community and diversity of 13-lined ground squirrels in the cecum lumen. Our study presents another step toward developing ground squirrels as a model for studying the interaction between the microbiota and host inflammation.
- | Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
Journal: Telencephalic stab wound injury induces regenerative angiogenesis and neurogenesis in zebrafish: unveiling the role of vascular endothelial growth factor signaling and microglia. (Pubmed Central) - Sep 9, 2024
Finally, we showed that inhibition of microglia by clodronate-containing liposome injection or dexamethasone treatment impairs regenerative neurogenesis, as previously described, as well as injury-induced angiogenesis...In addition, we have shown that both angiogenesis and neurogenesis are involved in brain repair and that microglia and inflammation-dependent mechanisms activated by Vegf signaling are important contributors to these processes. This study paves the way for a better understanding of the effect of Vegf on microglia and for studies aimed at promoting angiogenesis to improve brain plasticity after brain injury.
- | dexamethasone / Generic mfg.
Journal: Oligodendroglioma patient survival is associated with circulating B-cells and age. (Pubmed Central) - Sep 9, 2024
This study paves the way for a better understanding of the effect of Vegf on microglia and for studies aimed at promoting angiogenesis to improve brain plasticity after brain injury. Patients with oligodendrogliomas (141) were median age at diagnosis of 44 years; 57% male; 75% White; 60% prior chemotherapy; and 25% on dexamethasone at sample collection...Peripheral blood immune profiles in oligodendroglioma suggested that younger patients with lower B-na
- || azvudine (FNC) / Granlen
Review, Journal: Repurposing existing drugs for the treatment ofCOVID-19/SARS-CoV-2: A review of pharmacological effects and mechanism of action. (Pubmed Central) - Sep 9, 2024
The difficulty of studying these candidates in clinical trials involving COVID-19 patients, dosage of repurposed drugs, etc. is discussed in detail. Ultimately, Metformin is more suitable for prophylactic administration or mildly ill patients; the combination of Oseltamivir, Tamoxifen, and Dexamethasone is suitable for moderately and severely ill patients; and more clinical trials are needed for Azvudine, Ribavirin, Colchicine, and Cepharanthine to demonstrate efficacy.
- || dexamethasone / Generic mfg., sevoflurane / Generic mfg., dexmedetomidine / Generic mfg.
Clinical, Journal: The Effect of Opioid-Free Anesthesia with Transversus Abdominis Plane Block on Patients Undergoing Laparoscopic Sleeve Gastrectomy: Randomized Controlled Study. (Pubmed Central) - Sep 9, 2024
Sevoflurane, dexamethasone, and muscle relaxants were administered intraoperatively to all patients...The length of the hospital stay was significantly shorter compared with the control group (p =0.002). OFA with TAP results in a significant decrease in the need for antiemetic rescue, a lower level of pain after the surgery, and a shorter hospital stay in contrast with anesthesia based on opioids.
- | Tavalisse (fostamatinib) / Rigel, Rituxan (rituximab) / Roche
Journal: Is There a Correlation Between Immune Thrombocytopenia and Immunoglobulin G4-Related Disease? (Pubmed Central) - Sep 9, 2024
Fostamatinib provided temporary relief, but platelet count dropped again in 2023. Combination therapy with small doses of prednisone and mycophenolate showed a partial response, maintaining platelet count over 50
- | Mycobutin (rifabutin) / Pfizer, Lupin
Journal: Rifabutin-Induced Thrombocytopenia in a Patient With Uncontrolled HIV: A Case Report. (Pubmed Central) - Sep 9, 2024
Combination therapy with small doses of prednisone and mycophenolate showed a partial response, maintaining platelet count over 50 While the thrombocytopenia was resistant to transfusion and intravenous immunoglobulin (IVIG), it
- | Cytovene (ganciclovir) / Roche
Journal: Epstein-Barr Virus-Associated Aggressive Natural Killer Cell Leukemia: Challenges and Emerging Therapies. (Pubmed Central) - Sep 9, 2024
However, her course was complicated by infections and multi-organ failure, resulting in her passing. This case highlights the rarity and challenges in managing EBV-associated ANKL, emphasizing the need for early detection and improved treatment options, with stem cell transplantation
- || voriconazole / Generic mfg.
Retrospective data, Review, Journal: Associated factors with voriconazole plasma concentration: a systematic review and meta-analysis. (Pubmed Central) - Sep 9, 2024
Particular attention may be paid to age, albumin levels in children, and the use of omeprazole, pantoprazole, dexamethasone and methylprednisolone in adults. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42023483728.
- | Melflufen (melphalan flufenamide) / Oncopeptides
Journal: The emerging role of melflufen and peptide-conjugates in multiple myeloma. (Pubmed Central) - Sep 9, 2024
Single agent melflufen initially showed promising results especially in specific subgroups of heavily pretreated patients before the decision to suspend all clinical trials evaluating this agent after results from the OCEAN phase 3 trial. Subsequent reported analyses especially for melflufen-based combinations appear promising and suggest a potential use of peptide-drug conjugates provided optimal patient selection, as well as identification of the best companion agent.
- | hydrocortisone / Generic mfg.
Journal: Corticosteroid use in neonatal hypotension: A survey of Canadian neonatologists. (Pubmed Central) - Sep 8, 2024
While corticosteroids are frequently prescribed, there is variability in the indication, dosing, and duration of corticosteroid use. The findings from this survey can be used to inform further research, including a clinical trial, regarding the practice in the management of neonatal hypotension.
- | Journal: The (reverse) paradox of lupus anticoagulant: A case report. (Pubmed Central) - Sep 8, 2024
On follow up, child was doing well and her prothrombin time and complement levels had normalized. Low dose aspirin was aspirin was added for thromboprophylaxis.
- || dexamethasone / Generic mfg., sunitinib / Generic mfg.
PK/PD data, Preclinical, Journal: The CYP3A inducer dexamethasone affects the pharmacokinetics of sunitinib by accelerating its metabolism in rats. (Pubmed Central) - Sep 8, 2024
The impact of interactions on sunitinib metabolism, as observed with CYP3A inducers such as dexamethasone, is a crucial consideration for clinical practice. To optimize the dosage and prevent adverse drug events, therapeutic drug monitoring can be employed to avoid the toxicity from such interactions.
- | dexamethasone / Generic mfg.
Journal: Exploring alternative anthelmintic compounds: Impact of peruvin, hentriacontane/1-nonacosanol and their synergistic effect on the health of Meriones unguiculatus infected with Haemonchus contortus. (Pubmed Central) - Sep 8, 2024
Gerbils were artificially infected with H. contortus following dexamethasone treatment to enhance infection...The peruvin-treated group showed notable kidney damage, while hepatic alterations were similar across both compounds. Although effective, further research is needed to optimize dosing and ensure safety.
- | dexamethasone / Generic mfg., pioglitazone / Generic mfg.
Preclinical, Journal: The brain and systemic oxidative stress and memory changes induced by inhaled paraquat in rat improved by Crocus sativus. (Pubmed Central) - Sep 8, 2024
Although effective, further research is needed to optimize dosing and ensure safety. PQ groups were treated with 0.03
- | GTS21 / CoMentis
Journal: Identification of O-arylated huperzinines as novel cholinergic anti-inflammatory pathway agonists against gout arthritis. (Pubmed Central) - Sep 8, 2024
Meanwhile, these molecules possessed less cytotoxicity against promonocytic THP-1 macrophages when compared with colchicine. This work reports a concise strategy for direct modification of 2-pyridone moiety from natural Lycodine alkaloids, and provides novel frameworks for discovering CAP activators and drugs for gout arthritis.